Nestin Biosensor Quartz Crystal Microbalance for Early Glaucoma Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing glaucoma, such as ocular tonometry and proteomic analysis, are limited by complexity, cost, and require specialized personnel, and do not allow for early detection before visual impairment occurs.
Innovation Solution
A method using a biosensor functionalized with anti-nestin antibodies and a quartz crystal microbalance to quantify nestin in the aqueous humor for early diagnosis and prognosis of glaucoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunochemical techniques such as radioimmunoassay, immunofluorescence and immunoblotting are used to quantify nestin, then the diagnosis accuracy is improved, but the device complexity and operational difficulty increase
Solution Approach 1:
The patent replaces complex immunochemical techniques with a gravimetric measurement system based on quartz crystal microbalance. The biosensor captures nestin proteins on its surface, and the mass change is measured directly through frequency shift, eliminating the need for radioactive markers, complex incubation procedures, and specialized interpretation equipment.
Solution Approach 2:
The patent introduces a biosensor as an intermediary element that functionalizes anti-nestin antibodies on its surface. This biosensor acts as a mediator between the aqueous humor sample and the measurement system, enabling specific nestin detection through simple mass measurement without requiring complex immunochemical reagents or equipment.
2Reliability
If traditional immunochemical techniques are used, then nestin can be detected, but the procedure time and incubation duration increase
Solution Approach 1:
The biosensor is pre-functionalized with anti-nestin antibodies before use, preparing the detection surface in advance. This preliminary action eliminates the need for time-consuming in-lab antibody incubation steps, allowing direct measurement of nestin in the aqueous humor sample with significantly reduced procedure time.
3Measurement precision
If specialized personnel are used for result interpretation, then diagnostic accuracy is improved, but the operational complexity and training requirements increase
Solution Approach 1:
The patent replaces subjective interpretation processes with objective gravimetric measurement. The quartz crystal microbalance provides direct numerical readout of nestin mass through frequency measurement, eliminating the need for specialized personnel to interpret complex immunoblotting or immunofluorescence images.
Solution Approach 2:
The measurement system is designed to provide self-explanatory results through direct mass measurement. The frequency shift directly correlates to nestin concentration, providing an automatic, objective reading that does not require expert interpretation, thereby simplifying operation and reducing training requirements.
4Reliability
If early diagnosis before visual impairment is achieved, then patient prognosis is improved, but the detection sensitivity requirements increase
Solution Approach 1:
The patent uses gravimetric measurement with quartz crystal microbalance, which offers high sensitivity for mass detection. This mechanical measurement system can detect very small mass changes corresponding to low nestin concentrations, enabling early diagnosis before visual impairment occurs.
Solution Approach 2:
The biosensor is designed with high local concentration of anti-nestin antibodies on its surface, enhancing the local capture efficiency of nestin proteins. This localized functionalization improves the sensitivity of detection, enabling reliable measurement even at early stages when nestin levels are low.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides an easy, fast, and sensitive diagnosis of glaucoma before visual impairment, without the need for labeling or specialized interpretation, allowing for objective quantification and prognosis based on nestin levels.
Implementation Method 1
measuring the change of oscillation frequency of the quartz crystal
Implementation Method 2
measuring the change of oscillation frequency of the quartz crystal by quartz crystal microbalance
Implementation Method 3
adding an aqueous humor sample on said biosensor; measuring the change of oscillation frequency
Data Source
AI summary
The present invention relates to a method for the early diagnosis of glaucoma based on the quantification of nestin in the aqueous humor of a patient.